ATE538813T1 - Serumthymischer faktor zur behandlung von oxidativem stress bei allergien - Google Patents

Serumthymischer faktor zur behandlung von oxidativem stress bei allergien

Info

Publication number
ATE538813T1
ATE538813T1 AT01958548T AT01958548T ATE538813T1 AT E538813 T1 ATE538813 T1 AT E538813T1 AT 01958548 T AT01958548 T AT 01958548T AT 01958548 T AT01958548 T AT 01958548T AT E538813 T1 ATE538813 T1 AT E538813T1
Authority
AT
Austria
Prior art keywords
proteins
factor
drugs
lead
pharmaceutical compositions
Prior art date
Application number
AT01958548T
Other languages
English (en)
Inventor
Akira Awaya
Takashi Onodera
Tomohito Kakegawa
Original Assignee
Akira Awaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akira Awaya filed Critical Akira Awaya
Application granted granted Critical
Publication of ATE538813T1 publication Critical patent/ATE538813T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AT01958548T 2000-08-28 2001-08-28 Serumthymischer faktor zur behandlung von oxidativem stress bei allergien ATE538813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000256943 2000-08-28
PCT/JP2001/007354 WO2002017965A1 (fr) 2000-08-28 2001-08-28 Compositions medicinales

Publications (1)

Publication Number Publication Date
ATE538813T1 true ATE538813T1 (de) 2012-01-15

Family

ID=18745480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958548T ATE538813T1 (de) 2000-08-28 2001-08-28 Serumthymischer faktor zur behandlung von oxidativem stress bei allergien

Country Status (6)

Country Link
US (1) US20030186839A1 (de)
EP (1) EP1316315B1 (de)
JP (1) JP5035582B2 (de)
AT (1) ATE538813T1 (de)
AU (1) AU2001280199A1 (de)
WO (1) WO2002017965A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505290A (ja) * 2002-11-10 2006-02-16 インスティテュート オブ セル バイオフィジクス ロシアン アカデミー オブ サイエンシーズ 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
DE60304989T2 (de) * 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
WO2012075911A1 (zh) * 2010-12-06 2012-06-14 Li Jianyuan 重组人prx-6蛋白在治疗烧烫伤和/或角膜损伤中的用途
JP5804592B2 (ja) * 2011-04-22 2015-11-04 独立行政法人国立高等専門学校機構 抗アレルギーのための医薬品組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680276A (en) * 1977-05-25 1987-07-14 Institut National De La Sante Et De La Recherche Medicale Metal polypeptides
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5352665A (en) * 1987-11-24 1994-10-04 Mitsui Toatsu Chemicals, Incorporated Method of treating disease caused by the infection of virus
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5591446A (en) * 1989-04-04 1997-01-07 Beiersdorf, A.G. Methods and agents for the prophylaxis of atopy
JP3751986B2 (ja) * 1994-06-21 2006-03-08 英良 横沢 医薬組成物
JP3717955B2 (ja) * 1994-07-14 2005-11-16 道夫 藤原 医薬組成物
JP3784847B2 (ja) * 1994-09-26 2006-06-14 道夫 藤原 肝・胆管系疾患予防・治療剤
JP3728515B2 (ja) * 1994-10-24 2005-12-21 泰信 吉開 医薬組成物
JP2000103743A (ja) * 1998-09-29 2000-04-11 Jiyunji Yodoi チオレドキシン活性を有するファミリーに属するポリペプチド類を含有する食品、化粧品及び医薬

Also Published As

Publication number Publication date
EP1316315A4 (de) 2005-06-08
EP1316315A1 (de) 2003-06-04
JP5035582B2 (ja) 2012-09-26
WO2002017965A1 (fr) 2002-03-07
US20030186839A1 (en) 2003-10-02
AU2001280199A1 (en) 2002-03-13
JPWO2002017965A1 (ja) 2004-01-15
EP1316315B1 (de) 2011-12-28

Similar Documents

Publication Publication Date Title
PT863891E (pt) (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
WO2004019893A3 (en) Modulators of angiogenesis
ATE538813T1 (de) Serumthymischer faktor zur behandlung von oxidativem stress bei allergien
DE60100500D1 (de) Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
EP1080724A4 (de) Zusammenstellung die die mpt-aktivität mindert
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
DE69816047D1 (en) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE69333351D1 (de) Rekombinante lipase aus hundemagen und pharmazeutische zusammensetzungen
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
PT811068E (pt) Variantes da adnase i humana
Lee The role of NFATc1 on osteoblastic differentiation in human periodontal ligament cells
ATE317905T1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
Hayann et al. A nontoxic strontium nanoparticle that holds the potential to act upon osteocompetent cells: An in vitro and in vivo characterization
Fernandes et al. Mechanosignaling-related angiocrine factors drive osteoblastic phenotype in response to zirconia
Yang et al. Lactoferrin constitutively enhances differentiation of osteoblastic MC3T3-E1 cells in vitro
AU7079300A (en) Compositions and methods for the treatment of immune related diseases